Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

More documents

Recommendations

Info

Clinical Practice Characteristic Dyslipoproteinemia in Patients With Residual In Statin Treated Patients HDL Remains an Independent Risk Factor Cardiovascular Risk
LOW HDL-C AS A RESIDUAL RISK FACTOR FOR CARDIOVASCULAR EVENTS IN TNT Secondary Prevention TRIAL - Stable Cardiovascular Disease Major Cardiovascular Event Frequency (%) 14 12 10 8 6 4 2 0 54 HDL-C quintile (mg/dL) >100 70-100
Page 1 and 2: Treating Lipid Abnormalities Beyond
Page 3 and 4: THE PYRAMID OF CVD TRIALS Very high
Page 5 and 6: UNMET CLINICAL NEED TREATMENT OF TH
Page 7: Lipoprotein Metabolism in Patients
Page 11 and 12: THE BEGINNING …
Page 13 and 14: THE RESULT… OF THE SUPER SIZED LI
Page 15 and 16: Current Insights into the Mechanism
Page 17 and 18: Lipid Poor ApoA-I and αHDL αHDL i
Page 19 and 20: Intestine ApoA-I Current Model of H
Page 21 and 22: COLLAR-INDUCED CHANGES IN ENDOTHELI
Page 27 and 28: Potential Mechanisms Involved in th
Page 29 and 30: Increasing HDL By Infusion of HDL,
Page 31 and 32: HDL Targeted Therapies: Niacin 1. D
Page 33 and 34: HATS: Angiographic and Clinical End
Page 35 and 36: � � Aim High randomized 3414 pa
Page 37 and 38: Change in IVUS Total Atheroma Volum
Page 39 and 40: Future HDL Targeted Therapies 1. Pr
Page 41 and 42: Preβ-HDL Infusion Reduced Arterial
Page 43 and 44: Preβ-HDL Enriched Plasma Obtained
Page 45 and 46: The Reduction in Plaque was Greater
Page 47 and 48: Intestine ApoA-I Lipoprotein Profil
Page 49 and 50: 10 mg 30 mg 60 mg Plasma HDLC and L
Page 51 and 52: ILLUMINATE: Investigation of Lipid
Page 53 and 54: CETP Inhibitors CETP Torcetrapib Da
Page 55 and 56: The dal-HEART Program: Dalcetrapib
Page 57 and 58: LDL (mg/dL) Define Trial: Effect of
Page 59:
FUTURE THERAPY FOR CARDIOVASCULAR D
show all

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

Create successful ePaper yourself

Delete template?

Save as template?